Chicago Equity Partners LLC boosted its position in shares of OraSure Technologies, Inc. (NASDAQ:OSUR) by 53.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 120,355 shares of the medical instruments supplier’s stock after acquiring an additional 41,925 shares during the quarter. Chicago Equity Partners LLC owned 0.20% of OraSure Technologies worth $2,708,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of OSUR. BlackRock Inc. raised its position in OraSure Technologies by 127,593.4% during the first quarter. BlackRock Inc. now owns 7,743,325 shares of the medical instruments supplier’s stock worth $100,123,000 after acquiring an additional 7,737,261 shares in the last quarter. Daruma Capital Management LLC raised its position in OraSure Technologies by 2,761.0% during the second quarter. Daruma Capital Management LLC now owns 2,821,506 shares of the medical instruments supplier’s stock worth $48,699,000 after acquiring an additional 2,722,886 shares in the last quarter. Vanguard Group Inc. raised its position in OraSure Technologies by 30.3% during the first quarter. Vanguard Group Inc. now owns 4,466,499 shares of the medical instruments supplier’s stock worth $57,752,000 after acquiring an additional 1,037,439 shares in the last quarter. Acadian Asset Management LLC raised its position in OraSure Technologies by 32.5% during the second quarter. Acadian Asset Management LLC now owns 1,846,854 shares of the medical instruments supplier’s stock worth $31,877,000 after acquiring an additional 452,642 shares in the last quarter. Finally, Principal Financial Group Inc. raised its position in OraSure Technologies by 1,376.0% during the first quarter. Principal Financial Group Inc. now owns 455,208 shares of the medical instruments supplier’s stock worth $5,886,000 after acquiring an additional 424,368 shares in the last quarter. 92.56% of the stock is currently owned by hedge funds and other institutional investors.

Several research firms have issued reports on OSUR. ValuEngine lowered shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research report on Thursday, November 2nd. Canaccord Genuity increased their price objective on shares of OraSure Technologies from $21.00 to $22.00 and gave the company a “buy” rating in a research report on Thursday, August 3rd. Zacks Investment Research raised shares of OraSure Technologies from a “hold” rating to a “buy” rating and set a $25.00 price objective on the stock in a research report on Wednesday, September 20th. Jefferies Group LLC lowered shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research report on Thursday, November 2nd. Finally, BidaskClub lowered shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research report on Monday, July 31st. Four equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $18.21.

COPYRIGHT VIOLATION NOTICE: This news story was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another site, it was copied illegally and reposted in violation of US and international trademark and copyright law. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/11/12/chicago-equity-partners-llc-has-2-71-million-holdings-in-orasure-technologies-inc-osur.html.

OraSure Technologies, Inc. (NASDAQ:OSUR) opened at $14.25 on Friday. The firm has a market cap of $864.23, a PE ratio of 27.40, a PEG ratio of 2.74 and a beta of 1.39. OraSure Technologies, Inc. has a 1 year low of $7.84 and a 1 year high of $23.01.

OraSure Technologies (NASDAQ:OSUR) last issued its quarterly earnings data on Wednesday, November 1st. The medical instruments supplier reported $0.09 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.09. The company had revenue of $42.30 million for the quarter, compared to analyst estimates of $40.87 million. OraSure Technologies had a net margin of 20.48% and a return on equity of 14.12%. The company’s revenue was up 31.0% on a year-over-year basis. During the same period in the prior year, the firm earned $0.11 earnings per share. equities analysts anticipate that OraSure Technologies, Inc. will post 0.42 EPS for the current fiscal year.

In other OraSure Technologies news, Director Mara G. Aspinall purchased 5,000 shares of the stock in a transaction that occurred on Tuesday, November 7th. The shares were acquired at an average cost of $14.23 per share, with a total value of $71,150.00. Following the completion of the transaction, the director now owns 5,000 shares in the company, valued at $71,150. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Douglas A. Michels sold 22,923 shares of the firm’s stock in a transaction dated Wednesday, October 4th. The stock was sold at an average price of $23.00, for a total transaction of $527,229.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 61,110 shares of company stock worth $1,362,463. 6.40% of the stock is owned by insiders.

OraSure Technologies Profile

OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Want to see what other hedge funds are holding OSUR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OraSure Technologies, Inc. (NASDAQ:OSUR).

Institutional Ownership by Quarter for OraSure Technologies (NASDAQ:OSUR)

Receive News & Stock Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related stocks with our FREE daily email newsletter.